<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01476449</url>
  </required_header>
  <id_info>
    <org_study_id>1127228</org_study_id>
    <nct_id>NCT01476449</nct_id>
  </id_info>
  <brief_title>Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema</brief_title>
  <official_title>Monthly Ranibizumab Versus Treat and Extend Ranibizumab for Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Vitreous Associates of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Retina Vitreous Associates of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to see whether treating diabetic retinal swelling with ranibizumab injections
      into the eye monthly is better than treating diabetic retinal swelling with ranibizumab
      injections into the eye less frequently.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized study comparing two groups of patients with diabetic macular
      edema. One group will receive injections of ranibizumab monthly and the other group will have
      the option to receive injections of ranibizumab less frequently. That is eligible to receive
      the injections less frequently will have fewer injections given if the patients in that group
      are doing well.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Eye Chart Vision.</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>The ETDRS eye chart was used to assess vision at each visit, with the change through month 24 reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Injections.</measure>
    <time_frame>24 months</time_frame>
    <description>The average number of intravitreal ranibizumab injections in each arm of the study will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Spectral Domain Optical Coherence Tomography (SD-OCT) Central Foveal Thickness (CFT).</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate the average change in the swelling from diabetic macular edema measured with the optical coherence tomography machine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Best Corrected Visual Acuity (BCVA) Snellen-equivalent of 20/40 or Better.</measure>
    <time_frame>24 months</time_frame>
    <description>The percentage of patients with 20/40 vision as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 20 feet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Anatomically &quot;Dry.&quot;</measure>
    <time_frame>24 Months</time_frame>
    <description>Spectral domain OCT will be used to check the patients' central foveal thickness at each visit and the percentage with &quot;dry&quot; maculas at months 3,6, and 12 based on spectral domain OCT measurements per the study protocol will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Monthly Ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat and Extend Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically &quot;dry,&quot; at which point the evaluation and injection interval will be extended.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
    <arm_group_label>Monthly Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
    <arm_group_label>Treat and Extend Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age &gt; 18 years

          -  Patient related considerations

          -  Phakic or pseudophakic patients with a known history of diabetes will be eligible.

          -  Women of reproductive age will be required to take a urine pregnancy test prior to
             administration of the study drug.

          -  Disease related considerations:

          -  Patients will have met standard, accepted diagnostic criteria for diabetes and will be
             currently treated with at least one systemic antihyperglycemic or insulin medication.

          -  Patients will have a BCVA ETDRS Snellen-equivalent less than or equal to 20/40

          -  Central foveal thickness on SD-OCT of &gt;300um

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) or lactation Premenopausal women not using
             adequate contraception. The following are considered effective means of contraception:
             surgical sterilization or use of oral contraceptives, barrier contraception with
             either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or
             contraceptive hormone implant or patch.

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Participation in another simultaneous medical investigation or trial

          -  Foveal ischemia on IVFA

          -  Intraocular surgery less than 6 months ago

          -  Epiretinal membrane of clinical significance

          -  Prior vitrectomy

          -  Uncontrolled glaucoma

          -  Macular or peripheral laser within 90 Days from Day 0 injection

          -  Intravitreal steroid injection within 90 days from Day 0 injection

          -  Intravitreal or systemic anti-VEGF within 30 days from Day 0 injection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Eichenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Vitreous Associates of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Vitreous Associates of Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates of Florida</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.retinavitreous.com</url>
    <description>Study Sponsor: Retina Vitreous Associates of Florida</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 13, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <results_first_submitted>March 29, 2019</results_first_submitted>
  <results_first_submitted_qc>April 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2019</results_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>Diabetic Retinal Swelling</keyword>
  <keyword>DIabetic Eye Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Monthly Ranibizumab</title>
          <description>Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
        </group>
        <group group_id="P2">
          <title>Treat and Extend Ranibizumab</title>
          <description>Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically &quot;dry,&quot; at which point the evaluation and injection interval will be extended.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Monthly Ranibizumab</title>
          <description>Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
        </group>
        <group group_id="B2">
          <title>Treat and Extend Ranibizumab</title>
          <description>Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically &quot;dry,&quot; at which point the evaluation and injection interval will be extended.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" lower_limit="53" upper_limit="86"/>
                    <measurement group_id="B2" value="60.4" lower_limit="40" upper_limit="71"/>
                    <measurement group_id="B3" value="62.5" lower_limit="40" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Eye Chart Vision.</title>
        <description>The ETDRS eye chart was used to assess vision at each visit, with the change through month 24 reported.</description>
        <time_frame>Baseline through 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Monthly Ranibizumab</title>
            <description>Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
          </group>
          <group group_id="O2">
            <title>Treat and Extend Ranibizumab</title>
            <description>Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically &quot;dry,&quot; at which point the evaluation and injection interval will be extended.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Eye Chart Vision.</title>
          <description>The ETDRS eye chart was used to assess vision at each visit, with the change through month 24 reported.</description>
          <units>ETDRS Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="7.2"/>
                    <measurement group_id="O2" value="8.5" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Injections.</title>
        <description>The average number of intravitreal ranibizumab injections in each arm of the study will be recorded.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Monthly Ranibizumab</title>
            <description>Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
          </group>
          <group group_id="O2">
            <title>Treat and Extend Ranibizumab</title>
            <description>Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically &quot;dry,&quot; at which point the evaluation and injection interval will be extended.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Injections.</title>
          <description>The average number of intravitreal ranibizumab injections in each arm of the study will be recorded.</description>
          <units>injections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="5.9"/>
                    <measurement group_id="O2" value="18.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Spectral Domain Optical Coherence Tomography (SD-OCT) Central Foveal Thickness (CFT).</title>
        <description>Evaluate the average change in the swelling from diabetic macular edema measured with the optical coherence tomography machine.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Monthly Ranibizumab</title>
            <description>Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
          </group>
          <group group_id="O2">
            <title>Treat and Extend Ranibizumab</title>
            <description>Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically &quot;dry,&quot; at which point the evaluation and injection interval will be extended.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Spectral Domain Optical Coherence Tomography (SD-OCT) Central Foveal Thickness (CFT).</title>
          <description>Evaluate the average change in the swelling from diabetic macular edema measured with the optical coherence tomography machine.</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-169.0" spread="98.5"/>
                    <measurement group_id="O2" value="-146.8" spread="122.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Best Corrected Visual Acuity (BCVA) Snellen-equivalent of 20/40 or Better.</title>
        <description>The percentage of patients with 20/40 vision as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 20 feet.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Monthly Ranibizumab</title>
            <description>Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
          </group>
          <group group_id="O2">
            <title>Treat and Extend Ranibizumab</title>
            <description>Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically &quot;dry,&quot; at which point the evaluation and injection interval will be extended.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Best Corrected Visual Acuity (BCVA) Snellen-equivalent of 20/40 or Better.</title>
          <description>The percentage of patients with 20/40 vision as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 20 feet.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Anatomically &quot;Dry.&quot;</title>
        <description>Spectral domain OCT will be used to check the patients' central foveal thickness at each visit and the percentage with &quot;dry&quot; maculas at months 3,6, and 12 based on spectral domain OCT measurements per the study protocol will be recorded.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Monthly Ranibizumab</title>
            <description>Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
          </group>
          <group group_id="O2">
            <title>Treat and Extend Ranibizumab</title>
            <description>Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically &quot;dry,&quot; at which point the evaluation and injection interval will be extended.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Anatomically &quot;Dry.&quot;</title>
          <description>Spectral domain OCT will be used to check the patients' central foveal thickness at each visit and the percentage with &quot;dry&quot; maculas at months 3,6, and 12 based on spectral domain OCT measurements per the study protocol will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Monthly Ranibizumab</title>
          <description>Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
        </group>
        <group group_id="E2">
          <title>Treat and Extend Ranibizumab</title>
          <description>Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically &quot;dry,&quot; at which point the evaluation and injection interval will be extended.
Ranibizumab: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Death</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Suspected MI</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size, single-center, unmasked trial. This pilot study should be interpreted in the context of these limitations, yet may yield some guidance on one of the more common dosing methods for anti-VEGF medications in DME.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Eichenbaum, MD</name_or_title>
      <organization>Retina Vitreous Associates of Florida</organization>
      <phone>727-323-0077</phone>
      <email>deichenbaum@retinavitreous.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

